Experimental Alzheimers Drug Shows Early Promise

A new drug from Eli Lilly for Alzheimers shows promise cutting progression of the disease by 60% when administered early
(image via Depositphotos)

Trial data for a new experimental drug for Alzheimers shows early promise.

From Reuters:

An experimental drug from Eli Lilly (LLY.N) works best if Alzheimer’s patients are treated as early as possible, ideally before they develop symptoms of the brain-wasting disease, researchers said on Monday, in the latest promising development for treating the most common form of dementia.

The drug, donanemab, has been shown to slow progression of memory and thinking problems by about a third, but that rate doubles to 60% if the drug is started when patients are only mildly impaired, according to new trial data presented at the Alzheimer’s Association International Conference in Amsterdam.

Related: Researchers Develop Blood Test That Can Detect Early Alzheimers With 100% Accuracy